ESTRO 2025 - Abstract Book

S928

Clinical – Head & neck

ESTRO 2025

Keywords: nasopharyngeal carcinoma, marginal failure

References: 1.Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys . Mar 15 2000;46(5):1117-26. doi:10.1016/s0360-3016(99)00550-7 2.Liang SB, Sun Y, Liu LZ, et al. Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys . Nov 1 2009;75(3):742-50. doi:10.1016/j.ijrobp.2008.11.053

232

Digital Poster Low-dose Fractionated Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Phase II

Randomized Controlled Trial （ NCT05292027 ） Ming Fan 1,2,3 , Qingping Yin 4 , Lu Li 1 , Mei Feng 5,4

1 Radiation oncology, Sichuan cancer hospital, Chengdu, China. 2 Radiation oncology, Sichuan Clinical Research Center forCancer, Chengdu, China. 3 Radiation oncology, Affiliated Cancer Hospital of University of ElectronicScience and Technology of China, Chengdu, China. 4 Oncology, The third people's hospital of Sichuan province, Chengdu, China. 5 Radiation oncology, The third people's hospital of Sichuan province, Chengdu, China Purpose/Objective: The standard treatment for locally advanced nasopharyngeal cancer (LANPC) is induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT). However, for patients with extensive nodal involvement, the survival outcomes remain unsatisfactory. This prospective, randomized, controlled Phase II study aims to investigate the efficacy of combining LDFRT with IC for LANPC patients with adverse nodal factors.

Material/Methods:

Patients with Stage III-IVA nasopharyngeal cancer and high-risk nodal factors were randomized into LDFRT and control groups. High-risk nodal factors included N3 stage or N2 stage with at least one of the following features: lymph node central necrosis, extranodal invasion, and a shortest diameter of ≥3 cm. Patients received 3 cycles of IC with docetaxel